RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull

By Yahoo! Finance   |   4 months ago
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull

RAPT Therapeutics halts clinical programme for zelnecirnon due to FDA feedback after a patient needed a liver transplant. The company terminated Phase II trials for asthma and atopic dermatitis. They will focus on developing safer CCR4 compounds for inflammatory diseases.

Read More

Did you find this insightful?